Clinical trial · no report yet · Phase 3
MonumenTAL-3
A Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab and Pomalidomide Versus Daratumumab in Combination With Pomalidomide and Dexamethasone in Participants With Multiple Myeloma That Returns After Treatment or is Resistant to Treatment
- NCT05455320 ↗
- Active not recruiting
- Janssen Research & Development, LLC
- 70 commentary sources found
- Deep
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Commentary we found
Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built.
| Channel | Found | |
|---|---|---|
| X threads | 30 | |
| YouTube | 25 | |
| Podcasts | 14 | |
| X videos | 1 |
The trial
ClinicalTrials.gov- Official title
- A Phase 3 Randomized Study Comparing Talquetamab SC in Combination With Daratumumab SC and Pomalidomide (Tal-DP) or Talquetamab SC in Combination With Daratumumab SC (Tal-D) Versus Daratumumab SC, Pomalidomide and Dexamethasone (DPd), in Participants With Relapsed or Refractory Multiple Myeloma Who Have Received at Least 1 Prior Line of Therapy
- Phase
- Phase 3
- Status
- Active not recruiting
- Conditions
- Multiple Myeloma
- Interventions
- Talquetamab; Daratumumab; Pomalidomide; Dexamethasone
- Arms
- Arm A: Talquetamab Subcutaneous (SC) in Combination With Daratumumab SC and Pomalidomide (Tal-DP) · Experimental
- Arm B: Daratumumab in Combination With Pomalidomide and Dexamethasone (DPd) · Experimental
- Arm C: Talquetamab SC in Combination With Daratumumab SC (Tal-D) · Experimental
- Enrollment
- 864
- Primary outcomes
- Progression-Free Survival (PFS)
- Sponsor
- Janssen Research & Development, LLC
- Start
- Oct 13, 2022
- Primary completion
- Jul 30, 2027 (estimated)
- Results posted
- No
- Registry record
- NCT05455320 · updated Sep 25, 2026
Publications
linked from the registry- Mina R, Beksac M, Rodriguez-Otero P, Chen W, Mateos MV, Li J, Moreau P, Cohen YC, Min CK, Jelinek T, Ye JC, Magen H, Rubinstein SM, Fu W, Hungria V, Cengiz Seval G, Farias JS, Radocha J, Maral S, Turgut M, Koh Y, O'Leary D, Schmidt Filho J, Thertulien R, An G, Huang SY, Grosicki S, Tyczynska A, Banerjee R, Pianko MJ, Martinez-Lopez J, Steckiewicz P, Maruyama D, Fukushima K, Oriol A, Lopez Pardo J, Goldschmidt H, Pawlyn C, Perrot A, Zamagni E, Dimopoulos MA, Rasche L, Tolbert J, Terry W, Courtoux C, Liu X, Vasey SY, Connors K, Festa M, Heuck C, Langlois A, O'Rourke L, Zhou J, Qin X, Lu J, Gong J, Vieyra D, Voorhees PM; MonumenTAL-3 Investigators. Talquetamab-Daratumumab in Relapsed or Refractory Myeloma. N Engl J Med. 2026 Jun 13. doi: 10.1056/NEJMoa2604657. Online ahead of print. PubMed 42294841